Influenza A virus (IAV), a major cause of human morbidity and mortality, continuously evolves in 25 response to selective pressures. Stem-directed, broadly neutralizing antibodies (sBnAbs) targeting influenza 26 hemagglutinin (HA) are a promising therapeutic strategy, but neutralization escape mutants can develop. 27 We used an integrated approach combining viral passaging, deep sequencing, and protein structural 28 analyses to define escape mutations and mechanisms of neutralization escape in vitro for the F10 sBnAb. 29 IAV was propagated with escalating concentrations of F10 over serial passages in cultured cells to select 30 for escape mutations. Viral sequence analysis revealed three mutations in HA and one in neuraminidase 31 42 resistant or "escape" such antibodies, we propagated influenza A virus in vitro with escalating 43 concentrations of antibody and analyzed viral populations with whole genome sequencing. We identified 44 HA mutations near and distal to the antibody binding epitope that conferred resistance to antibody 45 neutralization. Additionally, we identified a neuraminidase (NA) mutation that allowed the virus to grow in 46 the presence of high concentrations of the antibody. Virus carrying dual mutations in HA and NA also grew 47 under high antibody concentrations. We show that NA mutations mediate the escape of neutralization by 48 on November 26, 2018 by guest http://jvi.asm.org/ Downloaded from 3 antibodies against HA, highlighting the importance of a balance between HA and NA for optimal virus 49 function.
(NA). Introduction of these specific mutations into IAV through reverse genetics confirmed their roles in 32 resistance to F10. Structural analyses revealed that the selected HA mutations (S123G, N460S, and N203V) 33 are away from the F10 epitope but may indirectly impact influenza receptor binding, endosomal fusion, or 34 budding. The NA mutation E329K, which was previously identified to be associated with antibody escape, 35 affects the active site of NA, highlighting the importance of the balance between HA and NA function for 36 viral survival. Thus, whole genome population sequencing enables the identification of viral resistance 37 mutations responding to antibody-induced selective pressure. 38 Importance 39 Influenza A virus is a public health threat for which currently available vaccines are not always 40 effective. Broadly neutralizing antibodies that bind to the highly-conserved stem region of influenza 41 hemagglutinin (HA) can neutralize many influenza strains. To understand how influenza virus can become 4 Introduction 51 Influenza A virus (IAV) causes a highly contagious acute respiratory illness in humans that is 52 responsible for significant morbidity and mortality. IAV's unique combination of evolutionary 53 mechanisms, including high mutation rate, segment reassortment, and shifts between multiple host species, 54 pose significant challenges for controlling the disease and developing effective vaccinations. The influenza 55 virion consists of eight negative-strand RNA segments which form protein-RNA complexes enveloped in a 56 lipid membrane (1). These eight segments encode at least ten proteins known to be essential for infectivity 57 and replication. The influenza polymerase lacks proofreading activity, resulting in a high spontaneous gene 58 mutation rate (2). Within a given influenza strain, sequence evolution proceeds by mutation, selection, and 59 genetic drift, all of which are affected by the host and by drug treatment. High mutation rates, together with 60 development of influenza epidemics, make tracing the evolutionary history of the virus and discovering the 61 principles governing IAV's evolution complex. Therefore a detailed understanding of IAV genome 62 sequence evolution is imperative. 63 IAV has two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA). HA helps the 64 viral genome enter the host cytoplasm through fusion of the viral membrane with the intracellular 65 endosomal membrane (3). NA cleaves sialic acid from the host cell membrane during the release of newly 66 formed viral progeny, thus reducing viral affinity for previously-infected cells (4). Eighteen different 67 subtypes of influenza A HA (H1-H18) exist, which are divided into two distinct groups, group 1 (H1, H2, 68 H5, H6, H8, H9, H11-H13, H16-H18) and group 2 (H3, H4, H7, H10, H14 and H15). HA is translated as a 69 single polypeptide (HA0) that is cleaved by host proteases into HA1 and HA2 subunits, HA functions as a 70 homo trimer composed of two copies of HA1 and one copy of HA2; the globular head (the receptor binding 71 site) is formed by HA1, and the stem (or "stalk") region is formed by both HA2 and HA1 and is responsible 72 for fusion [see (5) for review]. HA is the primary target of the humoral immune response during infection 73 or vaccination. Influenza vaccines generally elicit strain-specific responses with antibodies that target the 74 HA globular head, thereby limiting their efficacy and necessitating administration of new vaccines when a 75 on November 26, 2018 by guest http://jvi.asm.org/ Downloaded from novel strain becomes dominant. 76 Broadly neutralizing antibodies (BnAbs) bind to conserved epitopes on HA and can neutralize a 77 wide spectrum of influenza viruses (6). In influenza, BnAb epitopes typically correspond to receptor 78 binding and fusion machinery regions that are functionally conserved and thus less prone to mutation. 79 BnAbs are potential therapeutic agents when used as passive immunotherapy and can also be integrated 80 into the design of universal vaccines, which could provide protection against a broad range of influenza 81 strains and be much more effective than current vaccines. BnAbs against the influenza receptor-binding site 82 have limited neutralization capacity with each antibody effectively neutralizing a subset of strains in both 83 groups 1 and 2 (6-8). Several stem-directed broadly neutralizing antibodies (sBnAbs) against highly 84 conserved epitopes on the HA stem have been developed and characterized, including F10, C179, CR6261, 85 which neutralize group 1 variants; CR8020, which neutralizes group 2 variants; and CR9114, 3I14, and 86 39.29, which neutralize both groups 1 and 2 (6, 9-11). sBnAbs that neutralize group 1 viruses share an 87 epitope on the HA stem, while the epitope for group 2-specific antibodies is shifted toward the base of the 88 HA stem. Structural analyses revealed that differences in the binding footprints are due to conformational 89 constraints resulting from group-specific glycans on the HA stem (8). 90 sBnAbs prevent fusion of the host and virus membranes in the low pH of the endosome by locking 91 HA in a pre-fusion conformation and preventing the extensive conformational changes in HA required for 92 membrane fusion, blocking entry of viral RNA into the infected cell (8). Additional Fc-dependent 93 mechanisms also contribute to protection in vivo (12). Despite the high conservation of sBnAbs epitopes in 94 the HA stem region, neutralization escape mutations by sBnAbs have occurred in and around these epitopes 95 (6, 13-17). Many of these mutations cause neutralization escape by directly reducing antibody binding 96 affinity, but additional escape mechanisms that impact HA function or viral fitness may also emerge. A 97 recent mutational scanning study of H1 HA has shown that single amino acid mutations are more likely to 98 confer resistance against strain-specific antibodies that target the globular head of HA1 while similar 99 mutations in the stalk confer only modest resistance to neutralization by sBnAbs (18). Another study 100 on November 26, 2018 by guest http://jvi.asm.org/ Downloaded from 6 identified two escape mechanisms against a pan-IAV sBnAb, and some resistant viruses exhibited complete 101 abolition of antibody binding while others showed enhanced fusion ability by HA (11). Defining such 102 escape mechanisms is critical for evaluating sBnAbs to be incorporated into future vaccines and as 103 therapeutic strategies. 104 The F10 antibody, a sBnAb derived from the IGHV1-69 germline by panning immobilized HA 105 using phage-display libraries generated from healthy donors, is broadly active against all group 1 viruses 106 and protects mice from lethal H1N1 or H5N1 infection and reduces viral replication in lungs (9). sBnAbs 107 such as F10 bind to highly-conserved regions of HA that are required for the virus to function, so 108 characterizing sBnAb escape mutations that do not compromise virus survival provides insight for 109 influenza biology. The goal of the current study was to identify IAV escape mutants for the sBnAb F10 by 110 high throughput sequencing (HTS) analysis of virus populations generated through in vitro trajectory 111 experiments. To select for escape mutants, we propagated the virus under the selective pressure of 112 escalating concentrations of F10. Four mutations were identified, three in HA (none located in the F10 113 epitope) and one in NA, that were subsequently confirmed through reverse genetics to cause F10 resistance. 114 A combination of structural and dynamic analyses reveal possible molecular mechanisms by which these 115 mutations can confer F10 resistance. Thus, under the strict selective pressure of an antibody that targets an 116 evolutionarily conserved and functionally critical region, influenza virus selects for indirect mechanisms of 117 escape for survival. 120 We tested F10 against influenza A/Brisbane/59/2007 (H1N1) virus in Madin-Darby canine kidney 121 (MDCK) cells in our experimental trajectories (Figure 1) ). These candidate F10 escape mutations included three non-synonymous mutations in segment 4 134 encoding HA: N203V HA , N460S HA , and S123G HA (H1 numbering system) and one non-synonymous 135 mutation in segment 6 encoding NA, E329K NA . The selection of E329K NA was observed in both 136 trajectories with F10, but not with the 80R control. In addition, one non-synonymous mutation in segment 137 2, A643T PB1 , one non-synonymous mutation in segment 3, L28P PA , and synonymous mutations in segments 138 4 and 5 were identified. The synonymous changes appear consistent with genetic hitchhiking effects 139 associated with the above listed non-synonymous mutations, owing to their common trajectories. The allele 140 frequencies increased with each passage, and none of these mutations were elicited with the irrelevant 141 control 80R antibody or in the absence of antibody (Figure 2A) . Selection coefficients are shown in Figure   142 2B, and the posterior estimates of effective population size (N e ) are shown in Figure 2C . As expected, N e is 143 reduced in the challenged population. Segment 4 mutations A638G and A639T generate a double mutant in 144 perfect linkage to encode the N203V HA amino acid substitution. 146 A reverse genetics approach was employed to generate influenza virus A/Brisbane/59/2007 bearing 147 individual mutations S123G HA , N203V HA , N460S HA , E329K NA and the oseltamivir resistance mutation 148 H275Y NA (N1 numbering) as a control. Consistent with results from the serial passaging experiment, the 8 mutations S123G HA , N203V HA , N460S HA , and E329K NA each conferred resistance to F10 relative to wild 150 type (WT), as demonstrated by higher viral titers in the presence of F10 ( Figure 3A) . The HA mutants 151 (N460S HA , S123G HA , and N203V HA ) and NA mutant (E329K NA ) grew to higher titers than WT in the 152 presence of >0.7 g/mL of F10, while the control mutant H275Y NA had titers comparable to that of WT 153 virus. Of interest, the double mutant N203V HA _E329K NA had slightly higher titers at the intermediate 154 concentration of 1.3 g/mL of F10 than each mutant individually, suggesting that adaptation to F10 may 155 involve a complex and concentration-dependent fitness landscape. EC 50 and EC 90 calculations revealed that 156 all resistant mutations exhibited higher EC 90 values compared to WT ( Table 2) , although the EC 50 for the 157 E329K NA mutation was comparable to that of WT. The oseltamivir EC 50 values for WT, E329K NA , and 158 H275Y NA were also determined ( Figure 3B ). Oseltamivir EC 50 values for WT, E329K NA , and H275Y NA are 159 0.2, 3.0, and 86.6 M, respectively. E329K has been shown to reduce NA enzymatic activity relative to 160 WT A/Brisbane/59/2007 (23), which is consistent with the increase of oseltamivir's effective concentration 161 for E329K NA compared to WT. Overall, the reverse genetics enabled generating virus harboring the 162 individual selected mutations from in vitro passaging and confirming that these mutations confer resistance 163 to F10. 164 We measured the plaque diameter of individually cloned viruses to determine the fitness of the 165 identified escape mutations in HA and NA. In the absence of selection pressure by F10, the plaque sizes of 166 N460S HA and S123G HA mutants were similar to that of WT. However, the plaque sizes of N203V HA and 167 E329K NA were smaller than that of WT (Figure 4) . This observation is consistent with studies that showed 168 that the E329K NA mutation, which was previously identified as important for antigenic drift, reduces NA 169 enzyme activity and virus fitness (33). Plaques for the double mutant N203V HA _E329K NA were even 170 smaller, possibly reflecting the effects of both mutations. Thus, while high titers of N203V HA were 171 observed in the presence of F10, N203V HA appeared less fit based on plaque size.
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Serial passage of influenza A virus in the presence of F10
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F10 resistance validated by reverse genetics of individual mutant viruses
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Structural mapping of F10 escape mutants in HA
To further investigate the mutations selected in HA and identify escape mechanisms, we mapped 174 the non-synonymous mutations N460S HA , S123G HA , and N203V HA onto available crystal structures. 175 Notably, the mutations are located away from the F10 binding epitope (Figure 5) . Instead of directly 176 affecting F10 antibody binding, these distal mutations likely cause antibody escape through indirect 177 mechanisms. Influenza RNA enters the host cell and the viral envelope and the endosomal membrane fuse. 178 The N-terminal fragment of the HA2 subunit, or the fusion peptide, mediates fusion. At neutral pH, the 179 fusion peptide is buried in a negatively-charged pocket in the stem of HA, but at acidic pH, the fusion 180 peptide dissociates from the HA stem and inserts into the endosomal membrane to promote fusion between 181 the viral membrane and the endosomal membrane (5, 24, 25).
182
Two non-synonymous HA mutations selected by the F10 antibody in Experiment 1, N460S HA and 183 S123G HA , are located at key positions involved in the conformational changes needed to facilitate 184 membrane fusion (Figure 5) . The side chain of N460 forms an intermonomer hydrogen bond adjacent to 185 the fusion peptide which is broken when HA undergoes its conformational change upon fusion, thereby 186 exposing N460 (Figure 6) . N460 is the closest of the observed mutations to the F10 epitope on the HA 187 stem, as residues 17-21 of the fusion peptide form the center of the F10 epitope. In the N460S, the shorter 188 serine would be less likely to form this hydrogen bond and may alter the stability of the conformational 189 change in HA (26, 27). S123 is located at a hinge region of the HA1 subunit (Figure 7) . HA1 acts as a 190 clamp on HA2 and stabilizes the metastable prefusion state of HA (28). Upon fusion, HA1 undergoes 191 major conformational changes, one of which occurs around S123. In this region, an alpha helix begins to 192 unfold altering the adjacent antiparallel beta-sheet that connects to the receptor binding subdomain (28). 193 The mutation S123G introduces a flexible glycine residue into this hinge, which may facilitate this 194 conformational change. Thus both N460S HA and S123G HA likely alter the conformational stability of HA. 195 The final observed mutation N203V HA is located at the receptor-binding site of HA (Figure 8) . The from an acidic to a basic side chain. To investigate the effects of the E329K NA mutation on NA structure 209 and dynamics, the WT and E329K NA NA tetramer structures of influenza A/Brisbane/59/2007 strain were 210 modeled and 100 ns molecular dynamics (MD) simulations performed as we have previously described to 211 interpret resistant mutations in NA (37) and other systems (38-41). The electrostatic surfaces of the two 212 variants were compared, as E329K NA mutation constitutes an overall charge change of +8efor the 213 tetramer. Overall, the root mean square fluctuations (RMSFs, Figure 9A , B) of the active site in WT NA 214 were higher compared to E329K NA variant, altering the dynamics of the active site. Interestingly, even 215 though the E329K NA mutation is located far from the active site, the mutation had a distal effect and caused 216 the active site to become more positively charged (Figure 9C, D) . Thus, the E329K NA mutation had 217 propagating effects to alter the charge surface of the enzyme and fluctuations of the active sites, which may 218 underlie the decreased enzymatic activity previously reported for E329K NA relative to WT 219 A/Brisbane/ 59/2007 (23) . This alteration in substrate processing by NA may perturb the balance with HA 220 function and thus counter F10 inhibition.
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Discussion
BnAbs against influenza have invigorated the influenza field given their potential use for universal 223 therapies and vaccines that protect against a broad spectrum of strains and subtypes. However, antibody 224 neutralization escape mutations can emerge, and understanding neutralization escape together with the 225 underlying molecular mechanisms is critical for designing antibodies that are less prone to resistance. Here, 226 we identified and characterized F10 escape mutations for a vaccine strain of influenza virus, 227 A/Brisbane/59/2007, by combining viral passaging, HTS, reverse genetics, and structural analyses. We had 228 previously applied a similar approach to understand the temporal evolution of oseltamivir resistance (21, 229 42), viral reassortment (43), and mutagenesis induced by favipiravir (44, 45). In our current results, we 230 identified mutations in regions of HA that confer virus neutralization (i.e., blockade of viral replication) 231 and may modulate receptor binding specificity or fusion (46) or viral budding and release of progeny. We 232 also confirm F10 resistance conferred by an NA mutation previously identified to drive antigenic drift (47). 233 The F10 escape mutations identified in HA are not located at the antibody epitope, and thus rather 234 than directly modulating antibody binding, these mutations instead cause antibody escape by indirect 235 mechanisms. Mutations at residues 460 and 123 are located in regions of HA that modulate the pH of 236 fusion (46). Residue N460 (residue 117 of HA2 in H3 numbering) is located in the stem region surrounding 237 the fusion peptide, and mutations at nearby residues 111, 112, and 114 (H3 numbering) had previously 238 been reported to increase the pH of fusion in H3, H5, and H7 subtypes (30, 46, 48, 49) . Many other 239 mutations in the fusion peptide or the surrounding pocket have also been shown to significantly affect the 240 fusion activity of HA or the pH of membrane fusion (30, 46, 48-51). Residue S123 (residue 113 in H3 241 numbering) is located in a 110-helix that is involved in the reorganization of the HA1-HA2 interface that 242 occurs during membrane fusion, and mutations at residues 104, 110, and 115 (in H3 numbering) can impact 243 the pH of fusion due to changes at the HA1-HA2 interface (46, 52). Mutations at residue 203 (190 in H3 244 numbering) have been reported to impact receptor specificity for substrates with an α-2,3 or α-2,6 245 glycosidic linkage between the terminal sialic acid and the adjacent carbohydrate (47, 53-56). For instance, 246 the mutation E190D HA in combination with G225D HA (H3 numbering) in H1 increases specificity for α-2,6 12 linked sialic acids and reduces affinity for α-2,3 linked sialic acids (56). Such mutations that alter receptor-248 binding affinity are selected in response to other neutralizing antibodies as well (57, 58). Overall, we found 249 that under the selective pressure of a sBnAb that has a highly conserved epitope, mutations distal to the 250 antibody binding epitope in HA are selected to enable antibody escape. 251 In addition to mutations in HA, we found a mutation in NA that confers F10 resistance. This balance between HA and NA that is essential for optimal virus infectivity (59). Our structural analyses here 259 revealed the molecular mechanism by which the distal E329K mutation impacts the NA active site, likely 260 modulating enzymatic activity and the functional HA/NA balance in conferring F10 neutralization escape 261 of IAV. Our data demonstrate the plasticity of escape and the emergence of strong, off-target resistance via 262 the NA protein. 263 A closer inspection of experimental trajectories suggests that the E329K NA mutation may confer 264 resistance against F10 in combination with N203V HA . Once the E329K NA mutation with reduced NA 265 activity emerges and reaches a high frequency in the population (Figure 2A, P5 in Experiment 1), the 266 appearance of the N203V HA mutation restores the HA-NA functional balance and the drug pressure is 267 effectively reduced thus allowing for further fine-tuning of resistance. These mutations occur in the 268 opposite order in Experiment 2, in which N203V HA reaches a high frequency at P7, then E329K NA reaches 269 a similarly high frequency at P10-11 (see Figure 2A) . That both trajectories finally stabilized with the two 270 mutations N203V HA and E329K NA suggests that there is an interdependence in conferring resistance to F10. were also observed to similarly increase in frequency. However, their overlapping allele frequency 288 trajectories with the identified non-synonymous mutations strongly suggest linked, rather than direct, 289 selection (i.e., genetic hitchhiking). 290 In summary, we identified mutations at HA and NA that promote resistance to the sBnAb F10 in 291 vitro. Our results provide further evidence that mutations in one of these functionally complementary 292 proteins in IAV can facilitate mutations in the other thus shaping the evolutionary landscape of the virus 293 (62). While the serial passaging and HTS approaches may fail to distinguish functionally interacting 294 mutations from those simply linked by genetic hitchhiking effects (that is, a beneficial mutation linked to 295 an otherwise neutral, or even weakly deleterious, mutation), mutant viruses individually generated by 296 reverse genetics confirmed a functional interplay between N203V HA and E329K NA . This result highlights the importance of considering not only focal point mutations, but also the variable fitness effects induced 298 by the genetic backgrounds on which those mutations occur. IAV can use diverse and indirect molecular 299 mechanisms to escape neutralization by sBnAbs. An in-depth understanding of genome-wide effects of 300 sBnAbs on different IAV subtypes will yield insights on which "universal" influenza vaccines may be the 301 most effective and least likely to induce escape mutants. Furthermore, additive and synergistic effects of 302 single and combinations of HA and NA mutations on virus replication in the presence and absence of 303 antiviral drugs and sBnAbs can be monitored to define and quantify the impact of multiple selective 304 pressures on the evolution of resistance over time. Given that these will be "real world" pressures faced by 305 IAV, such combination studies will be invaluable for determining which combinations may serve as 306 optimal therapeutic strategies in treating future epidemics and pandemics. increased to 2X the EC 50 , and then doubled for each subsequent passage as long as >50% cytopathic effect 331 (CPE) was present. If <50% CPE was present, the concentration of antibody was escalated at a slower rate.
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Materials and Methods
332
Determination of the EC 50 and EC 90 for F10 antibody. The EC 50 and EC 90 values were defined as the 333 concentration of antibody that reduced plaque number to 50% or 90% of no drug control, respectively. In 334 brief, 3 x 10 4 MDCK cells/well were seeded in a 96-well plate and incubated overnight at 37 °C, 5% CO 2 . 335 Virus was added to cells at a multiplicity of infection (MOI) of 0.01 in 50 μL of influenza virus growth 336 medium [EMEM/10% FBS with 2 mM penicillin/streptomycin, 7.5% bovine serum albumin, and 1 g/mL 337 TPCK-treated-trypsin (Sigma)] plus serial dilutions of F10 antibody. After incubation at 37 °C for 1 h, cells 338 were washed once with PBS; 200 μL of influenza virus growth medium with the appropriate concentration 339 of antibody was added and cells were again incubated at 37 °C for several days. Supernatants were 340 collected when >90% CPE was achieved for at least one antibody concentration. Supernatants were 341 centrifuged for 15 min at 300 × g at 4 °C and stored at -80 °C. The viral titer for each sample was 342 determined by plaque assay. Resulting data were fit to a standard binding equation (variable slope, four 343 parameters) in order to estimate EC 50 and EC 90 values with GraphPad Prism Version 7 (La Jolla, CA).
High-throughput sequencing.
We developed a high-throughput sample processing workflow, carried out 345 in a 96-well format, including RNA purification, reverse transcription, whole genome PCR, followed by 346 DNA barcoding and library preparation, as previously described (42). Libraries were sequenced on the 347 Illumina HiSeq2000 platform to generate 100 nucleotide reads. 
